Please assess the completion status of the following clinical trial:

Trial Title: Tirofiban in Stenting for Long Coronary Lesion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18y\~80y, with symptomatic coronary disease~* At least one lesion length more than 40mm to be treated by overlapping drug-eluting stents in major epicardial coronary vessel~Exclusion Criteria:~* Aspirin or clopidogrel intolerance~* Lesions length less than 40mm, or overlapping stent length less than 40mm~* Bifurcation lesions need to be treated by two stents~* Patients with acute coronary syndrome and elevated baseline cardiac enzyme (CK-MB)~* Left ventricular ejection fraction less than 0.35~* Baseline estimated GFR less than 30~* Estimated life time less than one year~* Refuse to sign the informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): normal saline was applied to those randomized to control group, with same use as tirofiban
- Tirofiban group (Type: EXPERIMENTAL): after angioram, and before guiding catheter engagement: 10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).